New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:34 EDTRGEN, BMRNRepligen announces asset purchase agreement with BioMarin for HDACi Portfolio
Repligen (RGEN) announced that it has entered into an asset purchase agreement with BioMarin Pharmaceutical (BMRN) to advance Repligen's histone deacetylase inhibitor, or HDACi, portfolio. The HDACi portfolio includes multiple orally bioavailable small molecule compounds as well as enabling technologies. Under the terms of the agreement, Repligen will receive an upfront payment of $2M from BioMarin and it has the potential to receive up to $160M in future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. In addition, Repligen is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. Potential applications of the HDACi portfolio include Friedreich's ataxia and other neurological disorders.
News For RGEN;BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
13:30 EDTBMRNDeutsche Bank says BioMarin, AbbVie could have room to run
Subscribe for More Information
07:57 EDTBMRNDeutsche sees AbbVie, BioMarin outperforming near-term
Deutsche Bank analyst Robyn Karnauskas expects shares of AbbVie (ABBV) and BioMarin (BMRN) to outperform in the near-term following recent weakness in the biotech sector. On AbbVie, Karnauskas thinks data readouts in 2015 could add $15-$25 per share over time. For BioMarin, the analyst thinks only three of the five pipeline readouts need to work in 2015. The company's takeout valuation could be up to $217 per share if data for BMN-111 for Achondroplasia, Drisapsrsen for Duchenne muscular dystrophy and BMN 270 for hemophilia are positive, Karnauskas believes. The analyst also recommends buying Celgene (CELG) and Alexion (ALXN) on any weakness for upside in the second half of 2015.
May 1, 2015
09:43 EDTBMRNMacro weakness may prove to be gift for Biomarin investors, says Baird
Subscribe for More Information
07:43 EDTBMRNBioMarin price target raised to $125 from $120 at JPMorgan
JPMorgan raised its price target for BioMarin to $125 calling the company's Q1 results "solid." The firm keeps an Overweight rating on the name.
06:18 EDTBMRNBioMarin Q1 strong, risk/reward favorable into data, says Citigroup
Citigroup views BioMarin's Q1 results as strong and likes the risk/reward on shares into the "multiple" data readouts and the potential approval of drisapersen expected in the second half of 2015 in U.S and in 2016 in Europe. Citi raised its price target for shares to $135 from $133 and keeps a Buy rating on the name.
April 30, 2015
19:01 EDTBMRNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Ellie Mae (ELLI), up 10%... Ocwen Financial (OCN), up 9%... athenahealth (ATHN), up 8.5%... Expedia (EXPE), up 4.5%... Skyworks Solutions (SWKS), up 3.7%... Eastman Chemical (EMN), up 2.4%... Nektar Therapeutics (NKTR), up 1.4%... FireEye (FEYE), up 2%. ALSO HIGHER: Monsanto (MON), up 3.6% following a Bloomberg report that the company approached Syngenta (SYT) about a takeover... Altera (ALTR), up 4.4% following a Reuters report that Intel (INTC) has a standstill pact set to end in June. DOWN AFTER EARNINGS: LinkedIn (LNKD), down 21.3%... Hutchinson Technology (HTCH), down 15.3%... Insulet (PODD), down 13.9%... Accuray (ARAY), down 14%... Constant Contact (CTCT), down 9.9%... Trimble Navigation (TRMB), down 6.6%... First Solar (FSLR), down 4.4%... JDS Uniphase (JDSU), down 3%... BioMarin (BMRN), down 1.8%... Visa (V), down 1.6%.
16:14 EDTBMRNBioMarin sees 2015 revenue $850M-$880M vs. previous $840M-$870M
Subscribe for More Information
16:13 EDTBMRNBioMarin reports Q1 GAAP EPS (43c), consensus (53c)
Reports Q1 revenue $203.3M, consensus $202.82M. Reports Q1 Vimizim revenue $50.6M vs. $0.9M last year, Naglazyme revenue $78.2M vs. $80.1M last year.
15:01 EDTBMRNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Visa (V), consensus 62c... Gilead Sciences (GILD), consensus $2.32... American International (AIG), consensus $1.19... Public Storage (PSA), consensus $1.93... LinkedIn (LNKD), consensus 56c... BioMarin Pharmaceutical (BMRN), consensus (53c)... Expedia (EXPE), consensus 9c... Skyworks Solutions (SWKS), consensus $1.13... FleetCor (FLT), consensus $1.40... Eastman Chemical (EMN), consensus $1.60... Western Union (WU), consensus 38c... Fluor (FLR), consensus 98c... Fortune Brands Home & Security (FBHS), consensus 32c... Envision Healthcare (EVHC), consensus 26c... Agnico Eagle Mines (AEM), consensus 10c... FireEye (FEYE), consensus (51c)... Trimble Navigation (TRMB), consensus 30c... PerkinElmer (PKI), consensus 46c... Genpact (G), consensus 25c... athenahealth (ATHN), consensus 14c... Seattle Genetics (SGEN), consensus (19c)... HEALTHSOUTH (HLS), consensus 56c... Teradyne (TER), consensus 12c... Superior Energy (SPN), consensus (5c)... Eldorado Gold (EGO), consensus 2c... Regal Entertainment (RGC), consensus 12c... JDS Uniphase (JDSU), consensus 9c... MRC Global (MRC), consensus 18c... Boyd Gaming (BYD), consensus 9c... Ruckus Wireless (RKUS), consensus 8c... Cloud Peak Energy (CLD), consensus (12c).
April 29, 2015
07:46 EDTBMRNBioMarin has a conference call hosted by JPMorgan
Subscribe for More Information
April 27, 2015
09:44 EDTBMRNBioMarin completes rolling NDA submission to FDA for drisapersen for DMD
Subscribe for More Information
April 23, 2015
07:20 EDTRGENRepligen price target raised to $38 from $25 at Jefferies
Subscribe for More Information
April 21, 2015
14:00 EDTBMRNOptions with decreasing implied volatility
Options with decreasing implied volatility: NFLX MLNX XON WUBA MEMP BMRN FTNT BPT SNDK

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use